doi: 10.3389/fphar.2026.1752204 Received 22 November 2025 Revised 15 April 2026 Accepted 21 April 2026 Published 15 May 2026 Volume 17 - 2026 Edited by Sathish Kumar Natarajan, University of Nebraska-Lincoln, United States Reviewed by Fabio Vivarelli, University of Bologna, Italy Vijay Radhakrishnan, University of Missouri, United States Updates Copyright 2026 Mahalingam, Kharbanda, Casey and Rasineni
Consider combinations after lifestyle therapy and single-agent trials
First, the demographics in this trial are not reflective of the general U.S
It is particularly suitable for individuals who prefer not to take capsules or supplements daily, or who find oral routines difficult to maintain consistently
For context on the broader regulatory picture in 2026, Peptide Therapy and Mainstream Medicine in 2026 is worth reading alongside this guide